NEW YORK (GenomeWeb) – Cancer Genetics intends to use its recent purchase of BioServe Biotechnologies India as an entry point to make its tests available to customers on the subcontinent.

Cancer Genetics CEO Panna Sharma told BioArray News this week that the Rutherford, NJ-based molecular diagnostics firm will begin selling its FISH-based FHACT test for cervical cancer in India later this year, followed by the launch of its microarray-based MatBA-DLBCL test for the for the prognosis of diffuse large B-cell lymphoma in the first half of 2015.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.